Servier’s sevasemten came from the acquisition of the muscular dystrophy assets of Edgewise Therapeutics. While the small ...

For all the pink ribbons we see, women with breast cancer are abandoning one of the most effective treatments they have ...

Flagship Pioneering unveiled Etcelera, a new startup formed by combining three of the firm’s portfolio companies. Etcelera's ...

The FTC sent warning letters to 25 health plan marketers over potentially deceptive marketing practices, following its ...

To succeed, our healthcare system must fully embrace consumer-focused product design to address demands of scale, access, and ...

The U.S. Department of Health and Human Services (HHS) is rolling back several health IT certification requirements that ...

Corxel Pharmaceuticals is catching up to others with oral GLP-1 obesity drugs, but the biotech claims its small molecule ...

Health tech companies made several major funding announcements in October. Here is a list of some of the biggest funding ...

Midstream's Series A round was led by Valtruis, and included participation from Andreessen Horowitz (a16z), Foundry and ...

Setara Biosciences’ lead program is a potential treatment for the rare neuromuscular disorder Charcot-Marie-Tooth disease ...

Medical Microinstruments (MMI) has raised $125 million in Series D financing to expand the reach of its Symani Surgical ...

Gilead Sciences is getting global rights to an experimental PepStar Therapeutics oral peptide designed to inhibit the IL-23 ...